- Conditions
- Advanced Non-Small Cell Lung Cancer
- Interventions
- Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • La Jolla, California • Hollywood, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 1,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Neoplasm
- Interventions
- MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota
- Conditions
- Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Interventions
- decitabine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
- Conditions
- Carcinoma, Non-small-cell Lung
- Interventions
- erlotinib and bexarotene
- Drug
- Lead sponsor
- Konstantin Dragnev
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • New York, New York
- Conditions
- Lung Cancer
- Interventions
- irinotecan hydrochloride, paclitaxel
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Torrington, Connecticut
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- JNJ-86974680, Cetrelimab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Newnan, Georgia • Hackensack, New Jersey • Buffalo, New York + 4 more
- Conditions
- Advanced Solid Tumors, Non-small Cell Lung Cancer
- Interventions
- AMG 479, Everolimus, Panitumumab
- Drug
- Lead sponsor
- Jeffrey Clarke
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- Datopotamab Deruxtecan, Pembrolizumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 740 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 31
- States / cities
- Chandler, Arizona • Los Angeles, California • Santa Barbara, California + 19 more
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- NC318 800 mg, NC318 400 mg, Pembrolizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- PF-02341066, PF-00299804
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Bethesda, Maryland • Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- ZD6474, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
- Interventions
- JDQ443, TNO155, tislelizumab
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lung Cancer
- Interventions
- docetaxel, vinorelbine tartrate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 96
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Advanced Non-squamous Non-Small Cell Lung Cancer
- Interventions
- Pemetrexed, Carboplatin, Bevacizumab 7.5 mg/kg, Bevacizumab 15 mg/kg
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • Harvey, Illinois
- Conditions
- Lung Cancer, Nonsmall Cell
- Interventions
- IRX4204, erlotinib
- Drug
- Lead sponsor
- Io Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986466, Adagrasib, Cetuximab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- WSD0922-FU Tablets, Dose level A, WSD0922-FU Tablets, Dose level B
- Drug
- Lead sponsor
- Wayshine Biopharm, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Oxnard, California • Weston, Florida • Detroit, Michigan + 5 more
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
- Interventions
- HBI-2438
- Drug
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Encinitas, California • Glendale, California • Long Beach, California + 9 more
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
- Interventions
- OP-3136, Fulvestrant, Palazestrant
- Drug
- Lead sponsor
- Olema Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more
- Conditions
- Solid Tumors, Prostate Cancer
- Interventions
- ADI-PEG 20
- Drug
- Lead sponsor
- Polaris Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Rociletinib, Trametinib
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • Charlotte, North Carolina • Nashville, Tennessee + 1 more
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer, Advanced Cancer, Solid Tumor, Adult
- Interventions
- Lorigerlimab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 17
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 11 more
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Veno-occlusive Disease
- Interventions
- dalteparin, standard therapy
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 16 more